5-异丙基吡啶甲酸 | 26405-26-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 5-异丙基吡啶甲酸
• 中文别名: 5-异丙基皮考啉酸
• 英文名称: 5-isopropyl-2-pyridinecarboxylic acid
• 英文别名: 5-isopropenylpicolinic acid；5-Isopropylpicolinic acid；5-propan-2-ylpyridine-2-carboxylic acid
• CAS: 26405-26-5
• 化学式: C₉H₁₁NO₂
• mdl: MFCD00778356
• 分子量: 165.192
• InChiKey: MUACBAPXCBZBAC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  50.2
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2933399090

反应信息

• 作为反应物：
  描述：

  5-异丙基吡啶甲酸 、 (S)-2-amino-N-(2-((4-methoxyphenyl)amino)ethyl)-4-methylpentanamide 在 N,N-二异丙基乙胺 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 N-[(2S)-1-[2-(4-methoxyanilino)ethylamino]-4-methyl-1-oxopentan-2-yl]-5-propan-2-ylpyridine-2-carboxamide
  参考文献：
  名称：

  Arylaminoethyl Amides as Novel Non-Covalent Cathepsin K Inhibitors

  摘要：

  A series of N-alpha-benzyloxycarbonyl- and N-alpha-acyl-L-leucine(2-phenylaminoethyl)amide derivatives were prepared and evaluated for their inhibitory activity against rabbit and human cysteine proteases cathepsins K, L, and S. These data indicate that N-alpha-acyl-alpha-amino acid-(arylaminoethyl)amides represent a new class of selective non-covalent inhibitors of cathepsin K. Compounds 4b, 4e, and 4g exhibit high potency toward rabbit and human cathepsin K (IC50 < 0.006 muM) and are characterized by an excellent selectivity profile vs human cathepsins L and S.

  DOI：

  10.1021/jm010801s
• 作为产物：
  描述：

  2-甲基-5-(1-N乙基乙基)-吡啶 在 sodium hydroxide 、 potassium permanganate 、 水 、 双氧水 、 溶剂黄146 作用下， 以 水 为溶剂， 反应 37.67h， 生成 5-异丙基吡啶甲酸
  参考文献：
  名称：

  Schroetter, Eberhard; Schick, Hans; Teubner, Herbert, Journal fur praktische Chemie (Leipzig 1954), 1990, vol. 332, # 6, p. 1085 - 1087

  摘要：

  DOI：

文献信息

• Iminothiadiazine Dioxide Compounds as BACE Inhibitors, Compositions and Their Use
  申请人：Merck Sharp & Dohme Corp.

  公开号：US20150307465A1

  公开（公告）日：2015-10-29

  In its many embodiments, the present invention provides certain iminothiadiazine dioxide compounds, including compounds Formula (I): and include stereoisomers thereof, and pharmaceutically acceptable salts of said compounds stereoisomers, wherein each of R 1 , R 2 , R 3 , R 4 , R 5 , R 9 , ring A, ring B, m, n, p, -L 1 -, -L 2 -, and -L 3 - is selected independently and as defined herein. The novel iminothiadiazine dioxide compounds of the invention have surprisingly been found to exhibit properties which are expected to render them advantageous as BACE inhibitors and/or for the treatment and prevention of various pathologies related to β-amyloid (“Aβ”) production. Pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other active agents), and methods for their preparation and use in treating pathologies associated with amyloid beta (Aβ) protein, including Alzheimer's disease, are also disclosed.

  本发明提供了多种形式的亚氨基噻二唑二氧化物化合物，包括公式(I)的化合物： 包括它们的立体异构体，以及所述立体异构体的药用可接受盐，其中R1、R2、R3、R4、R5、R9、环A、环B、m、n、p、-L1-、-L2-和-L3-都是独立选择且按本文定义。发明的新型亚氨基噻二唑二氧化物化合物出人意料地被发现具有预期的特性，使其作为BACE抑制剂以及/或用于治疗和预防与β-淀粉样蛋白（“Aβ”）生成相关的各种病理学具有优势。还公开了包含一个或多个此类化合物（单独使用和与一个或多个其他活性成分组合使用）的药物组合物，以及它们的制备方法和用于治疗与淀粉样β（Aβ）蛋白相关的病理学，包括阿尔茨海默病的方法。
• METHOD FOR PRODUCING SPIROOXINDOLE DERIVATIVE
  申请人：DAIICHI SANKYO COMPANY, LIMITED

  公开号：US20160194331A1

  公开（公告）日：2016-07-07

  The present invention is intended to provide a method for efficiently producing and providing a compound having a spirooxindole skeleton, for example, a compound having a spirooxindole skeleton and having antitumor activity that inhibits the interaction between Mdm2 protein and p53 protein, or an intermediate thereof, using an asymmetric catalyst. A compound having an optically active tricyclic dispiroindole skeleton is efficiently obtained through a catalytic asymmetric 1,3-dipolar cycloaddition reaction using ketimine as a reaction substrate and using a chiral ligand and a Lewis acid.

  本发明旨在提供一种有效生产和提供具有螺环氧吲哚骨架的化合物的方法，例如，利用不对称催化剂制备具有螺环氧吲哚骨架并具有抗肿瘤活性的化合物，该化合物抑制Mdm2蛋白与p53蛋白之间的相互作用，或其中间体。通过使用酮亚胺作为反应底物，并使用手性配体和Lewis酸进行催化不对称1,3-二极环加成反应，有效地获得具有光学活性的三环二螺吲哚骨架的化合物。
• HETERO RING-FUSED IMIDAZOLE DERIVATIVE HAVING AMPK ACTIVATING EFFECT
  申请人：Tonogaki Keisuke

  公开号：US20130184240A1

  公开（公告）日：2013-07-18

  Disclosed is a compound which is useful as an AMPK activator. A compound represented by the formula: its pharmaceutically acceptable salt, or a solvate thereof, wherein a group represented by the formula: is a group represented by the formula: R 1 is each independently halogen, hydroxy, cyano, nitro, carboxy, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl or the like; m is an integer of 0 to 3; R 2 is hydrogen, or substituted or unsubstituted alkyl; X is —O—; and Y is substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.

  揭示了一种作为AMPK激活剂有用的化合物。一种由以下公式表示的化合物：其药学上可接受的盐，或其溶剂化合物，其中由以下公式表示的基团：是由以下公式表示的基团：R1是各自独立的卤素、羟基、氰基、硝基、羧基、取代或未取代的烷基、取代或未取代的烯烃基或类似物；m是0到3的整数；R2是氢，或取代或未取代的烷基；X是—O—；Y是取代或未取代的芳基，或取代或未取代的杂环芳基。
• MACROCYCLES AND THEIR USES
  申请人：Fujimoto Roger Aki

  公开号：US20090186830A1

  公开（公告）日：2009-07-23

  The present application describes organic compounds that are useful for the treatment, prevention and/or amelioration of diseases.

  本申请描述了对治疗、预防和/或改善疾病有用的有机化合物。
• [EN] BRIDGED HETEROCYCLIC COMPOUNDS AND METHODS OF USE<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES PONTÉS ET LEURS MÉTHODES D'UTILISATION
  申请人：MEDIVATION TECHNOLOGIES INC

  公开号：WO2011038164A1

  公开（公告）日：2011-03-31

  This disclosure relates to new compounds that may be used to modulate a histamine receptor in an individual. Novel compounds are described, including new bridged heterocyclic [4,3-b]indole compounds. Pharmaceutical compositions are also provided. Pharmaceutical compositions comprising the compounds are also provided, as are methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and/or a neuronal disorder.

  本披露涉及新化合物，可用于调节个体中的组胺受体。描述了新的化合物，包括新的桥式杂环[4,3-b]吲哚化合物。还提供了制药组合物。提供了包含该化合物的制药组合物，以及使用该化合物进行各种治疗应用的方法，包括治疗认知障碍、精神障碍、神经递质介导的障碍和/或神经元障碍。